{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:11:54Z","timestamp":1788469914719,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/pcan.2017.4","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T14:18:02Z","timestamp":1487686682000},"page":"276-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases"],"prefix":"10.1038","volume":"20","author":[{"given":"R","family":"McKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ristovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"BFpcan20174_CR1","volume-title":"Bone Cancer: Primary Bone Cancers and Bone Metastases","author":"FG Herrera","year":"2015","unstructured":"Herrera FG, Tawadros T, Berthold DR . Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions. In: Heymann D (ed). Bone Cancer: Primary Bone Cancers and Bone Metastases, 2nd edn. Elsevier Inc.: San Diego, CA; Elsevier\/Academic Press: Waltham, MA, 2015."},{"key":"BFpcan20174_CR2","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458\u20131468.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan20174_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15: 1147\u20131156.","journal-title":"Lancet Oncol"},{"key":"BFpcan20174_CR4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210\u20131217.","journal-title":"Lancet Oncol"},{"key":"BFpcan20174_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","volume":"68","author":"BA Gartrell","year":"2015","unstructured":"Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol 2015; 68: 850\u2013858.","journal-title":"Eur Urol"},{"key":"BFpcan20174_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15: 738\u2013746.","journal-title":"Lancet Oncol"},{"key":"BFpcan20174_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw065","volume":"27","author":"S Nilsson","year":"2016","unstructured":"Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016; 27: 868\u2013874.","journal-title":"Ann Oncol"},{"key":"BFpcan20174_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","volume":"66","author":"DE Rathkopf","year":"2014","unstructured":"Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014; 66: 815\u2013825.","journal-title":"Eur Urol"},{"key":"BFpcan20174_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/pcan.2012.42","volume":"16","author":"M Hagiwara","year":"2013","unstructured":"Hagiwara M, Delea TE, Saville MW, Chung K . Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 2013; 16: 23\u201327.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan20174_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2354.2009.01135.x","volume":"19","author":"RD Pockett","year":"2010","unstructured":"Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K . The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care 2010; 19: 755\u2013760.","journal-title":"Eur J Cancer Care"},{"key":"BFpcan20174_CR11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148\u20131159.","journal-title":"J Clin Oncol"},{"key":"BFpcan20174_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570\u2013579.","journal-title":"J Clin Oncol"},{"key":"BFpcan20174_CR13","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM . Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129\u2013138.","journal-title":"Ann Acad Med Singapore"},{"key":"BFpcan20174_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"CO Fritz","year":"2012","unstructured":"Fritz CO, Morris PE, Richler JJ . Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012; 141: 2\u201318.","journal-title":"J Exp Psychol Gen"},{"key":"BFpcan20174_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Eton DT . Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 2005; 28: 172\u2013191.","journal-title":"Eval Health Prof"},{"key":"BFpcan20174_CR16","first-page":"416","volume":"29","author":"JN Graff","year":"2015","unstructured":"Graff JN, Beer TM . Reducing skeletal-related events in metastatic castration-resistant prostate cancer. Oncology (Williston Park) 2015; 29: 416\u2013423.","journal-title":"Oncology (Williston Park)"},{"key":"BFpcan20174_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","volume":"68","author":"L Bourke","year":"2015","unstructured":"Bourke L, Boorjian SA, Briganti A, Klotz L, Mucci L, Resnick MJ et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol 2015; 68: 374\u2013383.","journal-title":"Eur Urol"},{"key":"BFpcan20174_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.eururo.2005.12.045","volume":"49","author":"F Saad","year":"2006","unstructured":"Saad F, Clarke N, Colombel M . Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006; 49: 429\u2013440.","journal-title":"Eur Urol"},{"key":"BFpcan20174_CR19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.18553\/jmcp.2010.16.9.693","volume":"16","author":"A Barlev","year":"2010","unstructured":"Barlev A, Song X, Ivanov B, Setty V, Chung K . Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010; 16: 693\u2013702.","journal-title":"J Manag Care Pharm"},{"key":"BFpcan20174_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","volume":"3","author":"H Hoefeler","year":"2014","unstructured":"Hoefeler H, Duran I, Hechmati G, Garzon Rodriguez C, Luftner D, Ashcroft J et al. Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries. J Bone Oncol 2014; 3: 40\u201348.","journal-title":"J Bone Oncol"},{"key":"BFpcan20174_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cmonc.2012.02.015","volume":"9","author":"A Mahmood","year":"2012","unstructured":"Mahmood A, Ghazal H, Fink M, Patel M, Atchison C, Wei R et al. Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: results of the US cohort from a multicenter observational study. Commun Oncol 2012; 9: 148\u2013157.","journal-title":"Commun Oncol"},{"key":"BFpcan20174_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","volume":"15","author":"V DePuy","year":"2007","unstructured":"DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F . Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007; 15: 869\u2013876.","journal-title":"Support Care Cancer"},{"key":"BFpcan20174_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579\u2013584.","journal-title":"Ann Oncol"},{"key":"BFpcan20174_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879\u2013882.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan20174_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","volume":"26","author":"C Yong","year":"2014","unstructured":"Yong C, Onukwugha E, Mullins CD . Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol 2014; 26: 274\u2013283.","journal-title":"Curr Opin Oncol"},{"key":"BFpcan20174_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14: 177\u2013183.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan20174_CR27","first-page":"317","volume":"14","author":"MJ Lage","year":"2008","unstructured":"Lage MJ, Barber BL, Harrison DJ, Jun S . The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008; 14: 317\u2013322.","journal-title":"Am J Manag Care"},{"key":"BFpcan20174_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.semnuclmed.2014.07.006","volume":"45","author":"AS Abi-Ghanem","year":"2015","unstructured":"Abi-Ghanem AS, McGrath MA, Jacene HA . Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med 2015; 45: 66\u201380.","journal-title":"Semin Nucl Med"},{"key":"BFpcan20174_CR29","first-page":"278","volume":"2","author":"M Sanford","year":"2013","unstructured":"Sanford M, Green K, Carroll P . The argument for palliative care in prostate cancer. Transl Androl Urol 2013; 2: 278\u2013280.","journal-title":"Transl Androl Urol"},{"key":"BFpcan20174_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59\u201369.","journal-title":"J Natl Cancer Inst"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan20174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan20174","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pcan.2017.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/pcan20174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:12:01Z","timestamp":1648674721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan20174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFpcan20174"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2017.4","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]},"assertion":[{"value":"24 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RM, MN and MF were employed by the Dana-Farber Cancer Institute (DFCI) at the time of the study. RM is currently employed by Moores Cancer Center and University of California. PK, currently employed by Memorial Sloan Kettering Cancer Center, was an employee of the DFCI at the time of the study. PK has served as a consultant to Astellas, Bayer, Janssen, Millennium\/Prometrika, Pfizer and Sanofi. RM has received institutional research funding from Bayer and Pfizer. MSD and BH are employees of Analysis Group, a consulting company that has received research grants from Bayer, including one for the current study. LR was an employee of the Analysis Group at the time of the study. AV and LW are employees of Bayer Healthcare, and LW owns Bayer stock. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}